Hormones release

Table 3. Effects of Ovine Somatotropin (oST) and Human Growth Hormone-Releasing Factor (hGRF) on Growth and Composition of Gain in Lambs ...

CCK is found in the digestive tract and the central and peripheral nervous systems. In the brain, CCK coexists with DA. In the peripheral nervous system, the two principal physiological actions of CCK are stimulation of gaU. bladder contraction and pancreatic enzyme secretion. CCK also stimulates glucose and amino acid transport, protein and DNA synthesis, and pancreatic hormone secretion. In the CNS, CCK induces hypothermia, analgesia, hyperglycemia, stimulation of pituitary hormone release, and a decrease in exploratory behavior. The CCK family of neuropeptides has been impHcated in anxiety and panic disorders, psychoses, satiety, and gastric acid and pancreatic enzyme secretions. 

Dopamine. Dopamine (DA) (2) is an intermediate in the synthesis of NE and Epi from tyrosine. DA is localized to the basal ganglia of the brain and is involved in the regulation of motor activity and pituitary hormone release. The actions of DA are terminated by conversion to dihydroxyphenylacetic acid (DOPAC) by monoamine oxidase-A and -B (MAO-A and -B) in the neuron following reuptake, or conversion to homovanillic acid (HVA) through the sequential actions of catechol-0-methyl transferase (COMT) and MAO-A and -B in the synaptic cleft. 

SRIF acts as an excitatory neuromodulator in the CNS inhibiting the release of TRH, corticotropin-releasing hormone (CRH), growth hormone releasing factor (GHRH), and NE. It produces general arousal and hypotension. It inhibits the release of a number of peptides and modulators in the GI tract. 

J (339), a 28-amino acid peptide, is a member of a family of stmctuially related peptides that includes secretin [1393-25-5] (340), growth hormone releasing factor (GRF), and pituitary adenylate cyclase-activating peptide (PACAP) [137061(341) (83). 

Somatostatin [38916-34-6] M 1637.9, [a]p -36 (c 0.57, 1% AcOH). A tetradecapeptide which is purified by gel filtration on Sephadex G-25, eluting with 2N AcOH, and then by liquid partition chromatography on Sepahdex G-25 using n-BuOH-AcOH-H20 (4 1 5) and has Rp= 0.4. It is a brain growth hormone releasing-inhibiting factor which has also been synthesised. [Burgus et al. Proc Natl Acad Sci USA 70 684 1973, Sorantakis and McKinley Biochem Biophys Res Commun 54 234 1973 Hartridt et al. Pharmazie 37 403 1982.]... 

LH-RH (Luteinizing Hormone-Releasing Hormone) agonists are drugs that inhibit the secretion of sex hormones. In men, LH-RH agonists cause testosterone levels to fall. In women, LH-RH agonists cause the levels of estrogen and other sex hormones to fall. 

Somatostatin SOM SST14 SST28 Somatotropin release inhibitory factor (SRIF) Growth hormone release-inhibiting factor... 

Somatostatin is a regulatory cyclic peptide, which has originally been described as a hypothalamic growth hormone release-inhibiting factor. It is produced throughout the central nervous system (CNS) as well as in secretoty cells of the periphery and mediates its regulatory functions on cellular processes such as neurotransmission, smooth muscle contraction, secretion and cell proliferation via a family of seven transmembrane domain G-protein-coupled receptors termed sstx 5. 

The diverse effects of somatostatin, such as inhibition of cell proliferation and hormone release, led to the suggestion that it could be used for the treatment of various diseases. However, its short plasma half-life (less than 3 min) and its relative low receptor subtype... 

Growth Hormone Release-inhibiting Factor GSK3... 

CN 6-[O-(l,l-dimethylethyl)-D-serine]-9-(N-ethyl L-prolinamide)-10-deglycinamideIuteinizing hormone-releasing factor (pig)... 

Somatostatin Growth hormone-release inhibiting factor (8,9) (51110-01-1)... 

HPLC High Performance Liquid Chromatography LHRH Lutenizing Hormone Releasing Hormone PTC Phase transfer catalyst SPPS Solid Phase Peptide Synthesis TFA Trifluoro acetic acid... 

---